Paul C Jou, MD
Dermatology · Poway
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Arch Health Partners Inc · 141 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Jou’s office at (858) 675-3100 to ask if they take your plan before you enroll.
California Medical Board record
Licence A148966 · Current
Licensed to practise in California · since 2017 · expires 2028-06-30 · Case Western Reserve University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$71,609
Medicare paid this office $71,609 for 203 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 110 | $14,468 | $86 |
| Destruction of skin growth, 1-14 growths | 67 | $8,412 | $93 |
| Short return visit (20+ min) | 81 | $6,606 | $64 |
| Destruction of precancer skin growth, 1 growth | 106 | $5,982 | $41 |
| Destruction of precancer skin growth, 15 or more growths | 33 | $5,751 | $131 |
See all 12 services
| Return visit (30+ min) | 110 | $14,468 | $86 |
| Destruction of skin growth, 1-14 growths | 67 | $8,412 | $93 |
| Short return visit (20+ min) | 81 | $6,606 | $64 |
| Destruction of precancer skin growth, 1 growth | 106 | $5,982 | $41 |
| Destruction of precancer skin growth, 15 or more growths | 33 | $5,751 | $131 |
| Destruction of precancer skin growth, 2-14 growths | 93 | $4,211 | $6 |
| Biopsy of related skin growth, first growth | 40 | $3,678 | $75 |
| New patient visit (45+ min) | 23 | $2,862 | $124 |
| New patient visit (30+ min) | 21 | $1,611 | $77 |
| Punch biopsy, first skin growth | 11 | $1,226 | $111 |
| Biopsy of related skin growth, each additional growth | 12 | $625 | $45 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 31 | $499 | $13 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 428 | More than 85% of doctors who do this |
| Removal or shaving of skin growth | 14 | More than 67% of doctors who do this |
| Skin biopsy | 67 | More than 72% of doctors who do this |
Who their Medicare patients are
203 Original Medicare patients in 2024. Average age 75 · Women 51% · Also on Medicaid 14% · Health risk score 1.00. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 68% · Diabetes 30% · Coronary heart disease 21% · Depression 18% · Chronic kidney disease 17% · Cancer 16% · COPD 13% · Atrial fibrillation 13% · Heart failure 11% · Dementia 6%.
The office billed $273,519, Medicare allowed $100,818 and paid $71,609; for 1,548 services of 55 kinds; $2,183 of it was for drugs given in the office and $69,427 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 203 | 1,548 | 75 | 1.00 | $273,519 | $71,609 |
| 2023 | 284 | 1,788 | 75 | 1.04 | $256,150 | $99,905 |
| 2022 | 275 | 1,469 | 75 | 1.11 | $226,455 | $89,633 |
| 2021 | 243 | 1,292 | 76 | 1.03 | $197,390 | $81,017 |
| 2020 | 238 | 1,399 | 75 | 1.04 | $180,281 | $68,111 |
| 2019 | 230 | 1,426 | 75 | 1.02 | $184,382 | $74,434 |
| 2017 | 144 | 583 | 70 | 1.50 | $110,151 | $26,183 |
| 2016 | 63 | 231 | 68 | 1.51 | $45,447 | $9,689 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Return visit (30+ min) | 159 | $20,500 | $97 |
| Destruction of skin growth, 1-14 growths | 104 | $10,724 | $89 |
| Destruction of precancer skin growth, 15 or more growths | 50 | $9,866 | $143 |
| Biopsy of related skin growth, first growth | 82 | $7,291 | $74 |
| New patient visit (45+ min) | 61 | $6,897 | $113 |
| Destruction of precancer skin growth, 1 growth | 120 | $6,022 | $39 |
| Short return visit (20+ min) | 73 | $5,924 | $64 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 15 | $4,814 | $267 |
| Destruction of precancer skin growth, 2-14 growths | 101 | $4,449 | $6 |
| Long return visit (40+ min) | 17 | $3,201 | $146 |
| Punch biopsy, first skin growth | 17 | $1,928 | $113 |
| Biopsy of related skin growth, each additional growth | 23 | $1,670 | $45 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 11 | $1,585 | $144 |
| New patient visit (30+ min) | 24 | $1,575 | $66 |
2022: 12 services
| Return visit (30+ min) | 133 | $19,665 | $99 |
| Destruction of skin growth, 1-14 growths | 98 | $11,620 | $91 |
| Destruction of precancer skin growth, 15 or more growths | 43 | $9,084 | $147 |
| New patient visit (45+ min) | 70 | $7,928 | $113 |
| Short return visit (20+ min) | 84 | $7,524 | $68 |
| Biopsy of related skin growth, first growth | 64 | $5,120 | $73 |
| Destruction of precancer skin growth, 1 growth | 97 | $4,715 | $40 |
| New patient visit (30+ min) | 40 | $3,107 | $78 |
| Destruction of precancer skin growth, 2-14 growths | 77 | $2,877 | $6 |
| Long return visit (40+ min) | 11 | $1,854 | $124 |
| Punch biopsy, first skin growth | 13 | $1,511 | $116 |
| Biopsy of related skin growth, each additional growth | 14 | $840 | $44 |
2021: 11 services
| Return visit (30+ min) | 117 | $16,992 | $99 |
| Destruction of skin growth, 1-14 growths | 84 | $10,235 | $93 |
| Short return visit (20+ min) | 105 | $9,009 | $71 |
| New patient visit (45+ min) | 52 | $6,137 | $118 |
| Destruction of precancer skin growth, 15 or more growths | 28 | $5,067 | $127 |
| Destruction of precancer skin growth, 1 growth | 91 | $4,998 | $42 |
| Biopsy of related skin growth, first growth | 56 | $4,482 | $73 |
| New patient visit (30+ min) | 40 | $3,559 | $89 |
| Destruction of precancer skin growth, 2-14 growths | 76 | $2,271 | $6 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 12 | $1,938 | $161 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 11 | $1,355 | $97 |
2020: 12 services
| Return visit (30+ min) | 111 | $11,904 | $79 |
| Short return visit (20+ min) | 82 | $5,700 | $52 |
| Destruction of skin growth, 1-14 growths | 52 | $5,220 | $86 |
| Destruction of precancer skin growth, 1 growth | 101 | $4,860 | $40 |
| Destruction of precancer skin growth, 15 or more growths | 30 | $4,476 | $124 |
| Biopsy of related skin growth, first growth | 58 | $4,423 | $68 |
| New patient visit (15+ min) | 62 | $3,255 | $52 |
| Destruction of precancer skin growth, 2-14 growths | 80 | $2,759 | $5 |
| New patient visit (30+ min) | 27 | $1,996 | $74 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 14 | $1,710 | $114 |
| Injection into skin growth, 1-7 growths | 12 | $461 | $31 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $19 | None |
2019: 10 services
| Return visit (30+ min) | 94 | $9,635 | $84 |
| Short return visit (20+ min) | 98 | $7,702 | $57 |
| Destruction of precancer skin growth, 1 growth | 112 | $6,335 | $43 |
| Destruction of precancer skin growth, 15 or more growths | 25 | $4,017 | $122 |
| Destruction of skin growth, 1-14 growths | 38 | $3,943 | $90 |
| Biopsy of related skin growth, first growth | 43 | $3,611 | $77 |
| New patient visit (15+ min) | 57 | $3,336 | $59 |
| Destruction of precancer skin growth, 2-14 growths | 94 | $2,589 | $5 |
| New patient visit (30+ min) | 29 | $1,981 | $68 |
| Short return visit | 11 | $427 | $39 |
2017: 10 services
| Biopsy of single growth of skin and/or tissue | 47 | $3,340 | $65 |
| Return visit (30+ min) | 37 | $3,123 | $74 |
| Short return visit (20+ min) | 38 | $2,717 | $48 |
| Destruction of skin growth, 1-14 growths | 29 | $2,708 | $77 |
| Destruction of precancer skin growth, 1 growth | 41 | $1,828 | $37 |
| New patient visit (30+ min) | 27 | $1,807 | $67 |
| New patient visit (15+ min) | 30 | $1,391 | $46 |
| Short return visit | 25 | $796 | $31 |
| Destruction of precancer skin growth, 2-14 growths | 35 | $486 | $4 |
| Biopsy of each additional growth of skin and/or tissue | 13 | $429 | $24 |
2016: 7 services
| Short return visit (20+ min) | 25 | $1,516 | $56 |
| Destruction of skin growth, 1-14 growths | 14 | $1,312 | $87 |
| Return visit (30+ min) | 15 | $1,208 | $81 |
| Biopsy of single growth of skin and/or tissue | 13 | $989 | $76 |
| New patient visit (15+ min) | 16 | $755 | $47 |
| Destruction of precancer skin growth, 1 growth | 17 | $624 | $37 |
| Destruction of precancer skin growth, 2-14 growths | 14 | $314 | $4 |
Medicaid work
$8,942 in 2024
Medicaid paid $8,942 for 70 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 56 | $6,973 |
| New patient visit (45+ min) | 14 | $1,970 |
| 2024 | 70 | 2 | 16 | $8,942 |
| 2023 | 136 | 2 | 19 | $16,899 |
| 2022 | 190 | 3 | 22 | $23,726 |
| 2021 | 55 | 2 | 15 | $6,991 |
| 2018 | 66 | 1 | 21 | $0 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 93 | $10,264 |
| New patient visit (45+ min) | 43 | $6,635 |
2022
| New patient visit (45+ min) | 103 | $14,484 |
| Return visit (30+ min) | 75 | $8,227 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 12 | $1,015 |
2021
| Return visit (30+ min) | 30 | $3,764 |
| New patient visit (45+ min) | 25 | $3,227 |
2018
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 66 | $0 |
Drugs they prescribed that Part D paid
$151,515
Pharmacies billed $151,515 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 518) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
457 generic and 61 brand-name prescriptions · $151,515 in drug cost · 34 antibiotic prescriptions to 26 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Otezla | 12 | $56,001 | $4,667 |
| Opzelura | 11 | $41,113 | $3,738 |
| Zilxi | 12 | $5,203 | $434 |
| Betamethasone Diprop Augmented | 35 | $1,402 | $40 |
| Fluocinolone Acetonide | 18 | $1,296 | $72 |
See all 15 drugs
| Otezla | 12 | $56,001 | $4,667 |
| Opzelura | 11 | $41,113 | $3,738 |
| Zilxi | 12 | $5,203 | $434 |
| Betamethasone Diprop Augmented | 35 | $1,402 | $40 |
| Fluocinolone Acetonide | 18 | $1,296 | $72 |
| Ketoconazole | 77 | $1,156 | $15 |
| Clobetasol Propionate | 28 | $1,126 | $40 |
| Fluocinolone Acetonide | 17 | $1,120 | $66 |
| Triamcinolone Acetonide | 57 | $634 | $11 |
| Ciclopirox | 25 | $515 | $21 |
| Dutasteride | 15 | $454 | $30 |
| Doxycycline Hyclate | 18 | $298 | $17 |
| Mupirocin | 16 | $151 | $9 |
| Finasteride | 18 | $97 | $5 |
| Methotrexate | 12 | $80 | $7 |
Year by year
| 2024 | 518 | 168 | 0% (0) | 12% | $151,515 |
| 2023 | 616 | 195 | 0% (0) | 6% | $62,344 |
| 2022 | 645 | 228 | 0% (0) | 7% | $50,026 |
| 2021 | 586 | 184 | 0% (0) | 12% | $135,058 |
| 2020 | 494 | 181 | 0% (0) | 11% | $62,709 |
| 2019 | 344 | 183 | 0% (0) | 12% | $132,710 |
| 2018 | 566 | 340 | 0% (0) | 16% | $94,965 |
| 2017 | 322 | 170 | None | 20% | $59,168 |
| 2016 | 127 | 63 | 0% (0) | 11% | $7,565 |
| 2015 | 18 | None | 0% (0) | None | $687 |
| 2014 | 66 | 25 | 0% (0) | 20% | $15,924 |
| 2013 | 34 | None | 0% (0) | None | $995 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Clobetasol Propionate | 57 | $4,630 | $81 |
| Ketoconazole | 84 | $2,961 | $35 |
| Betamethasone Diprop Augmented | 38 | $2,661 | $70 |
| Fluorouracil | 19 | $1,893 | $100 |
| Tacrolimus | 11 | $1,551 | $141 |
| Metronidazole | 20 | $1,388 | $69 |
| Fluocinolone Acetonide | 18 | $1,242 | $69 |
| Triamcinolone Acetonide | 79 | $1,205 | $15 |
| Clindamycin Phosphate | 20 | $962 | $48 |
| Fluocinolone Acetonide | 13 | $680 | $52 |
| Mometasone Furoate | 25 | $519 | $21 |
| Finasteride | 34 | $492 | $14 |
| Ciclopirox | 22 | $473 | $22 |
| Doxycycline Hyclate | 13 | $438 | $34 |
| Methotrexate | 22 | $323 | $15 |
| Ciclopirox | 11 | $248 | $23 |
| Folic Acid | 11 | $58 | $5 |
2022: 16 drugs
| Betamethasone Diprop Augmented | 80 | $7,367 | $92 |
| Ketoconazole | 93 | $3,013 | $32 |
| Clobetasol Propionate | 30 | $2,057 | $69 |
| Fluorouracil | 17 | $1,644 | $97 |
| Clindamycin Phosphate | 23 | $1,572 | $68 |
| Triamcinolone Acetonide | 100 | $1,371 | $14 |
| Metronidazole | 12 | $884 | $74 |
| Fluocinolone Acetonide | 11 | $781 | $71 |
| Mometasone Furoate | 22 | $743 | $34 |
| Valacyclovir | 12 | $717 | $60 |
| Dapsone | 12 | $481 | $40 |
| Mupirocin | 20 | $426 | $21 |
| Ciclopirox | 14 | $344 | $25 |
| Ciclopirox | 11 | $300 | $27 |
| Finasteride | 16 | $274 | $17 |
| Gabapentin | 13 | $252 | $19 |
2021: 14 drugs
| Otezla | 20 | $81,456 | $4,073 |
| Betamethasone Diprop Augmented | 84 | $5,396 | $64 |
| Fluorouracil | 29 | $2,471 | $85 |
| Ketoconazole | 56 | $1,723 | $31 |
| Valacyclovir | 13 | $1,718 | $132 |
| Triamcinolone Acetonide | 95 | $1,297 | $14 |
| Clobetasol Propionate | 17 | $1,266 | $74 |
| Mometasone Furoate | 28 | $856 | $31 |
| Clindamycin Phosphate | 12 | $808 | $67 |
| Metronidazole | 14 | $739 | $53 |
| Betamethasone Dipropionate | 11 | $704 | $64 |
| Doxycycline Hyclate | 12 | $554 | $46 |
| Dexamethasone | 15 | $357 | $24 |
| Mupirocin | 14 | $164 | $12 |
2020: 13 drugs
| Otezla | 11 | $41,484 | $3,771 |
| Betamethasone Diprop Augmented | 51 | $3,704 | $73 |
| Triamcinolone Acetonide | 95 | $1,613 | $17 |
| Metronidazole | 23 | $1,373 | $60 |
| Ketoconazole | 64 | $1,354 | $21 |
| Fluorouracil | 12 | $1,247 | $104 |
| Alclometasone Dipropionate | 24 | $1,176 | $49 |
| Clobetasol Propionate | 14 | $1,143 | $82 |
| Betamethasone Dipropionate | 22 | $1,096 | $50 |
| Dapsone | 13 | $838 | $64 |
| Mometasone Furoate | 17 | $541 | $32 |
| Mupirocin | 27 | $308 | $11 |
| Prednisone | 12 | $73 | $6 |
2019: 9 drugs
| Triamcinolone Acetonide | 74 | $1,961 | $27 |
| Fluorouracil | 21 | $1,899 | $90 |
| Alclometasone Dipropionate | 34 | $1,842 | $54 |
| Fluocinonide | 15 | $1,047 | $70 |
| Betamethasone Diprop Augmented | 20 | $899 | $45 |
| Ketoconazole | 44 | $841 | $19 |
| Clobetasol Propionate | 11 | $838 | $76 |
| Metronidazole | 16 | $790 | $49 |
| Mupirocin | 15 | $196 | $13 |
2018: 14 drugs
| Fluorouracil | 68 | $8,061 | $119 |
| Triamcinolone Acetonide | 86 | $3,878 | $45 |
| Betamethasone Diprop Augmented | 36 | $3,653 | $101 |
| Clobetasol Propionate | 27 | $3,400 | $126 |
| Fluocinonide | 39 | $3,399 | $87 |
| Tacrolimus | 13 | $3,205 | $247 |
| Alclometasone Dipropionate | 40 | $3,030 | $76 |
| Vectical | 13 | $1,375 | $106 |
| Metronidazole | 17 | $1,187 | $70 |
| Ketoconazole | 44 | $1,035 | $24 |
| Imiquimod | 18 | $558 | $31 |
| Retin-A | 12 | $508 | $42 |
| Mupirocin | 20 | $280 | $14 |
| Prednisone | 11 | $138 | $13 |
2017: 6 drugs
| Clobetasol Propionate | 21 | $4,137 | $197 |
| Betamethasone Dipropionate | 20 | $3,133 | $157 |
| Fluocinonide | 22 | $1,962 | $89 |
| Fluorouracil | 11 | $1,732 | $157 |
| Ketoconazole | 53 | $1,088 | $21 |
| Triamcinolone Acetonide | 45 | $673 | $15 |
2016: 3 drugs
| Fluocinonide | 15 | $1,704 | $114 |
| Ketoconazole | 22 | $657 | $30 |
| Triamcinolone Acetonide | 24 | $306 | $13 |
2014: 1 drug
| Triamcinolone Acetonide | 11 | $187 | $17 |
Money from drug and device companies
$848 in 2025
| 2025 | 12 | 41 | None | $848 |
| 2024 | 10 | 33 | None | $589 |
| 2023 | 12 | 43 | None | $875 |
| 2022 | 9 | 17 | None | $386 |
| 2021 | 4 | 4 | None | $78 |
| 2020 | 1 | 2 | None | $36 |
| 2019 | 6 | 13 | None | $395 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Tremfya | $243 | 13 payments
|
| Abbvie | Skyrizi | $137 | 7 payments
|
| Novartis Pharmaceuticals | Cosentyx | $76 | 3 payments
|
| Incyte | Opzelura | $71 | 3 payments
|
| Galderma Laboratories L.P. | Nemluvio | $70 | 4 payments
|
| Ucb | Bimzelx | $59 | 2 payments
|
See all 41 published payments
| Abbvie | Meals · 2025-12-18 | Skyrizi | $5 |
| Abbvie | Meals · 2025-12-12 | Skyrizi | $4 |
| Janssen Biotech | Meals · 2025-12-09 | Tremfya | $21 |
| Novartis Pharmaceuticals | Meals · 2025-12-03 | Cosentyx | $32 |
| Incyte | Meals · 2025-12-01 | Opzelura | $23 |
| Janssen Biotech | Meals · 2025-11-18 | Tremfya | $18 |
| Amgen | Meals · 2025-11-07 | Otezla | $19 |
| Abbvie | Meals · 2025-10-29 | Skyrizi | $28 |
| Abbvie | Meals · 2025-10-13 | Skyrizi | $19 |
| Janssen Biotech | Meals · 2025-09-09 | Tremfya | $24 |
| Incyte | Meals · 2025-09-03 | Opzelura | $28 |
| Janssen Biotech | Meals · 2025-08-19 | Tremfya | $21 |
| Amgen | Meals · 2025-08-15 | Otezla | $20 |
| Galderma Laboratories L.P. | Meals · 2025-08-13 | Nemluvio | $15 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-11 | Sotyktu | $23 |
| Novartis Pharmaceuticals | Meals · 2025-08-06 | Cosentyx | $26 |
| Sun Pharmaceutical Industries | Meals · 2025-08-04 | Ilumya | $20 |
| Janssen Biotech | Meals · 2025-07-16 | Tremfya | $22 |
| Ucb | Meals · 2025-07-14 | Bimzelx | $33 |
| Galderma Laboratories L.P. | Meals · 2025-07-02 | Nemluvio | $19 |
| Janssen Biotech | Meals · 2025-06-25 | Tremfya | $19 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-18 | Sotyktu | $20 |
| Kyowa Kirin | Meals · 2025-06-16 | Poteligeo | $20 |
| Incyte | Meals · 2025-06-11 | Opzelura | $20 |
| Amgen | Meals · 2025-05-28 | Otezla | $16 |
| Janssen Biotech | Meals · 2025-05-20 | Tremfya | $19 |
| Abbvie | Meals · 2025-05-14 | Skyrizi | $24 |
| Janssen Biotech | Meals · 2025-05-12 | Tremfya | $4 |
| LEO Pharma | Meals · 2025-05-12 | Adbry | $25 |
| Galderma Laboratories L.P. | Meals · 2025-05-08 | Nemluvio | $21 |
| Janssen Biotech | Meals · 2025-05-01 | Tremfya | $21 |
| Lilly USA | Meals · 2025-04-28 | Taltz | $29 |
| Galderma Laboratories L.P. | Meals · 2025-04-03 | Nemluvio | $15 |
| Janssen Biotech | Meals · 2025-03-18 | Tremfya | $21 |
| Novartis Pharmaceuticals | Meals · 2025-03-12 | Cosentyx | $19 |
| Janssen Biotech | Meals · 2025-02-27 | Tremfya | $20 |
| Abbvie | Meals · 2025-02-19 | Skyrizi | $27 |
| Janssen Biotech | Meals · 2025-01-27 | Tremfya | $9 |
| Janssen Biotech | Meals · 2025-01-21 | Tremfya | $24 |
| Abbvie | Meals · 2025-01-08 | Skyrizi | $29 |
| Ucb | Meals · 2025-01-06 | Bimzelx | $25 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $589
| Janssen Biotech | Tremfya | $185 | 15 payments
|
| LEO Pharma | Adbry | $85 | 3 payments
|
| Abbvie | Skyrizi | $72 | 3 payments
|
| Novartis Pharmaceuticals | Cosentyx | $58 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $56 | 3 payments
|
| Incyte | Opzelura | $36 | 2 payments
|
| Sun Pharmaceutical Industries | Ilumya | $28 | 1 payment
|
| Arcutis Biotherapeutics | Zoryve | $24 | 1 payment
|
| Almirall | Klisyri | $23 | 1 payment
|
| Amgen | Otezla | $21 | 1 payment
|
2023: $875
| Janssen Biotech | Tremfya | $194 | 13 payments
|
| LEO Pharma | Adbry | $121 | 5 payments
|
| Arcutis Biotherapeutics | None | $103 | 5 payments
|
| Dermavant Sciences | Vtama | $97 | 5 payments
|
| Amgen | Otezla | $84 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $80 | 4 payments
|
| Novartis Pharmaceuticals | Cosentyx | $62 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $36 | 1 payment
|
| Almirall | Klisyri | $29 | 1 payment
|
| Sun Pharmaceutical Industries | Ilumya | $28 | 1 payment
|
| Pfizer | Eucrisa | $22 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Cyltezo | $20 | 1 payment
|
2022: $386
| Genzyme | Dupixent | $129 | 5 payments
|
| Sun Pharmaceutical Industries | Ilumya | $67 | 2 payments
|
| Janssen Biotech | Tremfya | $44 | 3 payments
|
| Abbvie | Rinvoq | $41 | 2 payments
|
| LEO Pharma | Adbry | $26 | 1 payment
|
| Pfizer | Eucrisa | $23 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $23 | 1 payment
|
| Galderma Laboratories L.P. | Epsolay | $19 | 1 payment
|
| Ortho Dermatologics a division of Bausch Health US | Jublia | $13 | 1 payment
|
2021: $78
| Sun Pharmaceutical Industries | Ilumya | $24 | 1 payment
|
| Incyte | Opzelura | $20 | 1 payment
|
| Pfizer | Eucrisa | $19 | 1 payment
|
| Janssen Biotech | Tremfya | $14 | 1 payment
|
2020: $36
| VYNE Pharmaceuticals | Amzeeq | $36 | 2 payments
|
2019: $395
| Janssen Biotech | Tremfya | $170 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $86 | 3 payments
|
| Amgen | Enbrel | $48 | 2 payments
|
| Celgene | None | $47 | 2 payments
|
| Dermira | None | $30 | 1 payment
|
| Tactile Systems Technology | Flexitouch | $13 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.2 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1356608319
- Licence
- CA A148966, MN 58597California A148966: Current · expires 2028-06-30
- Trained
- Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University, 2012
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 15611 Pomerado Rd Ste 400, Poway, CA, 92064
- NPI first listed
- 2012-04-16
- NPI last updated
- 2022-07-21
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 14500 99th Ave N, Maple Grove, MN, 55369 · 900 Welsh Road Suite 300, Palo Alto, CA, 94304 · One Daniel Burnham Court Suite 350c, San Francisco, CA, 94109